|
C7ORF25 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.83749999996363E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.9744000001598E-07 |
| Normal-vs-Stage2 |
9.453200E-01 |
| Normal-vs-Stage3 |
1.65500000004482E-06 |
| Normal-vs-Stage4 |
5.79139999999922E-05 |
| Stage1-vs-Stage2 |
8.235700E-04 |
| Stage1-vs-Stage3 |
2.921200E-01 |
| Stage1-vs-Stage4 |
4.233800E-01 |
| Stage2-vs-Stage3 |
6.30320000000184E-05 |
| Stage2-vs-Stage4 |
9.242000E-04 |
| Stage3-vs-Stage4 |
9.509400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.14719999850288E-08 |
| Normal-vs-AfricanAmerican |
2.738000E-03 |
| Normal-vs-Asian |
1.762350E-03 |
| Caucasian-vs-AfricanAmerican |
8.775200E-01 |
| Caucasian-vs-Asian |
1.955210E-01 |
| AfricanAmerican-vs-Asian |
4.740200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.597140E-04 |
| Normal-vs-Female |
2.87560000000742E-06 |
| Male-vs-Female |
5.328800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.26030000166833E-08 |
| Normal-vs-Age(41-60Yrs) |
4.03140000000413E-05 |
| Normal-vs-Age(61-80Yrs) |
8.263400E-03 |
| Normal-vs-Age(81-100Yrs) |
1.851790E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.310400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.101900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.292800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.422800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.660800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.380400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.220230E-02 |
| Classical-VS-Follicular |
3.09229999995164E-06 |
| Classical-VS-Other |
9.075200E-01 |
| Classical-VS-Normal |
1.46989999949554E-07 |
| Tall-VS-Follicular |
6.04350000044107E-08 |
| Tall-VS-Other |
4.787400E-01 |
| Tall-VS-Normal |
2.04310000029295E-08 |
| Follicular-VS-Other |
1.215570E-01 |
| Follicular-VS-Normal |
5.348800E-01 |
| Other-VS-Normal |
4.329600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.102640E-03 |
| Normal-vs-N1 |
2.31340000000912E-06 |
| N0-vs-N1 |
1.518380E-02 |
|
|
